Archives

by in
Entry Author Date Location
East Coast Biotech Roundup: Acceleron, Seres, Sage, & More 07/18/14 Boston
Sage, Despite Industry-Wide Pullback, Scores $90M in Upsized IPO 07/17/14 Boston
Who Needs Biotech VCs, Anyway? 07/15/14 San Francisco
BIO 2014: An Industry Surrounded by Insurmountable Opportunity 06/19/14 San Diego
Sage Therapeutics Readies IPO Pitch to Develop CNS Drugs 06/18/14 Boston
Amid Court Fight and Trial Pauses, Juno Closes First Round at $176M 04/24/14 Seattle
Just 7 Tickets Left for Our What’s Hot in Cancer Event April 22 04/21/14 Seattle
Agios’s Blood Cancer Drug Shines in First Clinical Test 04/06/14 Boston
East Coast Biotech Roundup: ImmusanT, NY Disruptors, Tesaro, & More 03/14/14 Boston
Sage Therapeutics Grabs $38M More For CNS Drugs 03/13/14 Boston
SAGE Therapeutics Lands $38,000,000 Series C Round 03/13/14 Boston
Join Xconomy for ‘What’s Hot in Cancer Immunotherapy’ on April 22 02/20/14 Seattle
The Young and Proven Biotech VCs From 2012. Where Are They Now? 02/10/14 National
Juno Therapeutics Receives $120,000,000 Series A Financing Round 12/05/13 Seattle
Juno Therapeutics Grabs $120M to Coax Immune System to Fight Cancer 12/03/13 Seattle
East Coast Biotech Roundup: Pronutria, Alzheon, Nextcode, & More 10/25/13 Boston
NextCODE Lands $15,000,000 Series A Funding Round 10/24/13 Boston
DeCode Spinout, NextCode Health, Launches With $15M From Arch, Polaris 10/23/13 Boston
East Coast Biotech Roundup: Schenkein, PureTech/JDRF, Sage, & More 10/18/13 Boston
SAGE Therapeutics Receives $20,000,000 Series B Financing Round 10/16/13 Boston
Boreal Genomics Lands $18,000,000 Series C Round 10/07/13 San Francisco
Langer’s Bind Therapeutics Prices IPO at $15 Per Share 09/20/13 Boston
Boston Roundup: Acquia, 908 Devices, StarStreet 08/30/13 Boston
Fate Therapeutics Joins Biotech IPO Conga Line, Reaching for $69M 08/14/13 San Diego
Buoyed by Partnerships, Bind Therapeutics Floats $80.5M IPO Plan 08/12/13 Boston
VLST, After Nine Years and $50M, Sells Assets and Winds Down 08/07/13 Seattle
Ensemble Reels in Novartis to Develop Oral, Mid-Sized Inflammation Drugs 08/06/13 Boston
Celgene Emerges as Biotech’s Shrewdest, Nimblest Dealmaker 08/05/13 National
Agios Rockets to $29 Per Share in Market Debut 07/24/13 Boston
Agios Prices Upsized IPO Above Range, Preps For Nasdaq Debut 07/24/13 Boston
Page 1 of 13 next page »